In the News: Pharma Data Protection Rules; Facial Recognition Restrictions; and UBS Fully Owns Its Chinese Operations

China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.

Credit: Chexy139/Adobe Stock


China Releases Draft Rules on Data Protection in Pharmaceutical Trials


Chinese authorities have released draft measures to regulate the data protection period of pharmaceutical trials, including those from overseas.

Under the Implementing Measures for the Protection of Pharmaceutical Trial Data (Trial Implementation, Draft for Comments) (“Implementing Measures”) (药品试验数据保护实施办法（试行，征求意见稿）), (issued along with the Work Procedure for the Protection of Pharmaceutical Trial Data (Draft for Comments) (药品试验数据保护工作程序 (征求意见稿) ), the National Medical Products Administration (NMPA) proposes different data protection periods for three categories of drugs, according to an article by CMS Legal.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]